EUVIMEDEUVIMED entdecken
Crossref

Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain

María Nieto-Cid iD, Teresa Garriga-Baraut iD, Ana Mª Plaza-Martín, Miguel Tortajada-Girbés iD, Javier Torres-Borrego iD, Jaime Lozano-Blasco, Laura Moreno-Galarraga iD, Ma Del Mar Folqué-Giménez, Montse Bosque-García iD, Mirella Gaboli iD, Alejandro López-Neyra iD, Cristina Rivas-Juesas iD und 21 weitere

Pediatric Allergy and Immunology · 2023

DOI: 10.1111/pai.13942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2023. Verfasst von María Nieto-Cid und 32 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Allergy Unit, Hospital Universitari i Politècnic La Fe, Health Research Institute La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.

Methods

A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.

Results

The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.

Conclusion

The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaHumansChildOmalizumabCost-Benefit AnalysisSpainRetrospective StudiesTreatment OutcomeQuality of LifeSpiro Compounds

Stichwörter der Autor:innen

ICERbiologicscostomalizumabpharmacoeconomicssevere pediatric allergic asthma

Substanzen

OmalizumabAnti-Asthmatic Agentsspiropentaneacetic acidSpiro Compounds

Autor:innen und Institutionen

  • Pediatric Pulmonology and Allergy Unit, Hospital Universitari i Politècnic La Fe, Health Research Institute La Fe, Valencia, Spain.
  • Allergy Service, Hospital Universitario de La Plana, Villarreal, Spain.
  • Pediatric Allergy Unit, Hospital Universitari Vall d'Hebron. Grup d'Investigació "Creixement i Desenvolupament", Institut de Recerca de l'Hospital Universitari Vall d'Hebron (VHIR), Barcelona, Spain.
  • Allergy and Clinical Immunology Department, Hospital Materno-Infantil Sant Joan de Déu, Barcelona, Spain.
  • Pediatric Allergy and Pneumology Unit, Hospital Universitari Dr. Peset, Valencia, Spain.
  • Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain.

ORCID-Profile: María Nieto-Cid, Teresa Garriga-Baraut, Miguel Tortajada-Girbés, Javier Torres-Borrego, Laura Moreno-Galarraga, Montse Bosque-García, Mirella Gaboli, Alejandro López-Neyra, Cristina Rivas-Juesas, Mª Araceli Caballero-Rabasco, Andrea Freixa-Benavente, Laura Valdesoiro-Navarrete, Inés de Mir-Messa, Alfredo Valenzuela-Soria, Mercedes Sánchez-Mateos, Verónica Sanz-Santiago, Álvaro Gimeno-Díaz de Atauri, Anselmo Andrés-Martín, David Gómez-Pastrana, Genoveva Del Río-Camacho, Ángel Mazón-Ramos, Antonio Nieto-García

Zitieren

APA

Nieto-Cid, M., Garriga-Baraut, T., Plaza-Martín, A. M., Tortajada-Girbés, M., Torres-Borrego, J., Lozano-Blasco, J., Moreno-Galarraga, L., Del Mar Folqué-Giménez, M., Bosque-García, M., Gaboli, M., López-Neyra, A., Rivas-Juesas, C., Caballero-Rabasco, M. A., Freixa-Benavente, A., Valdesoiro-Navarrete, L., de Mir-Messa, I., Ballester-Asensio, E., Penín-Antón, M., Romero-García, R., …, & Nieto-García, A. (2023). Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13942

Vancouver

Nieto-Cid M, Garriga-Baraut T, Plaza-Martín AM, Tortajada-Girbés M, Torres-Borrego J, Lozano-Blasco J, et al. Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain. Pediatric Allergy and Immunology. 2023. doi:10.1111/pai.13942

BibTeX
@article{NietoCid2023,
  author = {Nieto-Cid, María and Garriga-Baraut, Teresa and Plaza-Martín, Ana Mª and Tortajada-Girbés, Miguel and Torres-Borrego, Javier and Lozano-Blasco, Jaime and Moreno-Galarraga, Laura and Del Mar Folqué-Giménez, Ma and Bosque-García, Montse and Gaboli, Mirella and López-Neyra, Alejandro and Rivas-Juesas, Cristina and Caballero-Rabasco, Mª Araceli and Freixa-Benavente, Andrea and Valdesoiro-Navarrete, Laura and de Mir-Messa, Inés and Ballester-Asensio, Esther and Penín-Antón, María and Romero-García, Raquel and Navarro-Morón, Juan and Valenzuela-Soria, Alfredo and Sánchez-Mateos, Mercedes and Batlles-Garrido, José and Sanz-Santiago, Verónica and de Atauri, Álvaro Gimeno-Díaz and Andrés-Martín, Anselmo and Campos-Alonso, Elena and Gómez-Pastrana, David and Vázquez-Rodríguez, Elena and Martínez-Pardo, Luz and Del Río-Camacho, Genoveva and Mazón-Ramos, Ángel and Nieto-García, Antonio},
  title = {Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain},
  journal = {Pediatric Allergy and Immunology},
  year = {2023},
  doi = {10.1111/pai.13942}
}
Kostenlos starten →